JOHN K. BARTOSZ, OF GOLD IN SEPTEMBER (G9), HONORED BY BAND OF PARENTS THROUGH THE FIRST PEDIATRIC IMMUNOTHERAPY FELLOWSHIP AT MEMORIAL SLOAN KETTERING CANCER CENTER

For Immediate Release

JOHN K. BARTOSZ, OF GOLD IN SEPTEMBER (G9), HONORED BY BAND OF PARENTS THROUGH THE FIRST PEDIATRIC IMMUNOTHERAPY FELLOWSHIP AT MEMORIAL SLOAN KETTERING CANCER CENTER

Delafield, Wis., May 4, 2016 – Tonight, at the Evening of Hope event in New York, the Band of Parents will announce The John K. Bartosz Memorial Fellowship in Pediatric Immunotherapy, the first-ever fellowship in pediatric immunotherapy at MSK, one of the 27 G9 Centers of Excellence, in honor of the late John K. Bartosz.

The John K. Bartosz Memorial Fellowship in Pediatric Immunotherapy at MSK is a one-year post graduate training opportunity for the pediatric hematologist oncologist with a continuing interest in the field of immunotherapies for pediatric cancers.

John K. Bartosz and his family traveled the world looking for cures for his son, Jack, battling neuroblastoma. Along the way, he met many other families in the same fight, seeking new, effective treatments and cures for their children. He never gave up hope for a better future, even when Jack lost his battle with neuroblastoma at the age of 10 in 2012.

John, himself, lived with the after effects of radiation and chemotherapy treatments that saved his life while in his 20's, but ultimately cost him his life in his 40's. “[On March 28, 2016,] the pediatric cancer community lost a leader, a champion and one of the most important people to influence the way the world sees the universe of pediatric cancer.

John Bartosz singlehandedly set up more pediatric cancer charities than any other attorney. He guided parents, families, and philanthropists of all kinds though the process and helped them join the battle. While actively helping run our own Band of Parents, he started the amazing I Back Jack Foundation and Gold In September® (G9) Charitable Trust. He sat on boards and gave mountains of solid advice,” said Marc Winthrop, Chairman of The Band of Parents, in a written tribute after learning of his friend’s passing.

MSK’s Department of Pediatrics is one of the largest in the world devoted to the treatment of childhood malignancies and is a renowned leader in the development of monoclonal antibody based immune therapy. The goal of this fellowship is to broaden the training of the recipient to translate immunotherapy strategies from the laboratory to the patient, including but not limited to clinical trial design, protocol development, Investigational New Drug (IND) application, and execution of clinical trials.

“It is an honor to know that John’s dedication and steadfast support of childhood cancer initiatives will live on in the hearts of all of us that loved him, and in the hearts of the children and families that will find hope in the innovative new treatment opportunities and outstanding medical professionals at Memorial Sloan Kettering Cancer Center, through The John K. Bartosz Memorial Fellowship in Pediatric Immunotherapy,” said wife, Sarah Bartosz.

 

About G9:

Gold In September® Charitable Trust (G9) is a registered 501(c)(3) tax-exempt organization dedicated to growing national awareness, inspiring action, and raising funds to help every child, everywhere until cures for cancer are found. With global research, strategic partners, and innovative solutions, G9 is a catalyst for change. Visit www.goldinseptember.com to learn more about G9.

 

About Band of Parents:

The Band of Parents is a member-based organization with the goal of funding new therapies for neuroblastoma, a rare and deadly cancer that only strikes children. Our mission is to seek projects that have already been examined in the lab and are in need of assistance to rapidly move into a patient population. To date, the Band has granted more than $5 million to pediatric cancer research. Learn more at www.bandofparents.org.

 

About Memorial Sloan Kettering Cancer Center:

Memorial Sloan Kettering Cancer Center is the world’s oldest and largest private cancer center, having devoted more than 130 years to exceptional patient care, innovative research, and outstanding educational programs. Today, it is one of 45 National Cancer Institute–designated Comprehensive Cancer Centers, with state-of-the-art science flourishing side by side with clinical studies and treatment. Memorial Sloan Kettering Cancer Center is committed to exceptional patient care, leading-edge research, and renowned educational programs. Learn more at www.mskcc.org.